SNS 062

Drug Profile

SNS 062

Alternative Names: SNS-062

Latest Information Update: 10 Apr 2017

Price : $50

At a glance

  • Originator Biogen Idec; Sunesis Pharmaceuticals
  • Developer Biogen; Sunesis Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Haematological malignancies

Most Recent Events

  • 03 Apr 2017 Pharmacodynamics data from preclinical studies in Haematological malignancies released by Sunesis Pharmaceuticals
  • 02 Mar 2017 Sunesis pharmaceuticals has patent protection for SNS 062 in USA, Europe and other countries (Sunesis pharmaceuticals form 10-K, March 2017)
  • 02 Mar 2017 Sunesis pharmaceuticals has patents pending for SNS 062 in USA, Europe and other countries (Sunesis pharmaceuticals form 10-K, March 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top